Takeda has shot down candidates acquired in its $525 million Maverick Therapeutics takeover, blowing a hole in its oncology R ...

Takeda UK Ltd. has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for rADAMTS13 ...

Takeda’s Julie Kim argues that Trump’s idea to match drug prices to that of other countries could cost the industry up to $1 ...

Takeda was scrambling to accommodate for rapidly sinking profits from the hasty decline of ADHD mainstay Vyvanse with a 140 ...

Christophe Weber, CEO of Takeda Pharma, discusses the group's plans to invest $30 billion into its U.S. operations over the ...

Q4 2024 Earnings Call Transcript May 9, 2025 Christopher O’Reilly: Thank you very much for taking time out of their busy ...

Takeda Pharmaceutical Co Ltd (TSE:4502) is set to release its Q4 2024 earnings on May 8, 2025. The consensus estimate for Q4 ...

UK MHRA grants marketing approval for Takeda’s Adzynma to treat congenital thrombotic thrombocytopenic purpura: United Kingdom Wednesday, May 14, 2025, 11:00 Hrs [IST] The Medic ...

Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & ...

NET LOSS FORECAST: Takeda is expected to post a net loss of 81.7 billion yen, equivalent to $573.7 million, for the three months ended March, according to a Visible Alpha poll of analysts. That ...